Reported Earlier, European Commission Approves Eisai And Biogen's Leqembi As First Disease-Modifying Therapy For Early Alzheimer's

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes with confirmed amyloid pathology

Lecanemab is the first therapy that targets an underlying cause of the disease to be authorized in the EU for eligible people with early AD